16.10.2015 • NewsDede WillamsJanssenclinical

J&J and enGene to Collaborate on IBD

Canada’s enGne, a gene therapy company focused on development of therapeutics using its proprietary “Gene Pill”, and Janssen Biotech, one of the Janssen Pharmaceutical Companies of US-based Johnson & Johnson, have agreed to jointly develop and commercialize new therapies for inflammatory bowel disease (IBD).

Under the agreement, enGene will receive an upfront payment and equity investment through Johnson & Johnson Innovation, along with R&D funding. The gene therapy specialist is also eligible to receive various pre-clinical, clinical, regulatory and commercialization success-based milestone payments up to a total of C$441 million, plus tiered royalties on potential net sales of products.

The alliance leverages enGene's proprietary non-viral vector platform for gene delivery to cells lining the intestine and provides Janssen with the option to exclusively license enGene's lead product candidate, EG-12, for gut-localized expression of the anti-inflammatory cytokine IL-10.

The Canadian and US companies will jointly develop EG-12 through to clinical proof of mechanism in patients with IBD. Upon exercise of its option, Janssen will take over further clinical development and commercialization of EG-12 for all indications worldwide. The collaboration also allows Janssen to explore the therapeutic potential of enGene's platform to deliver one additional undisclosed target.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.